<!DOCTYPE html>
<html class="client-js"><head>
  <meta charset=UTF-8"UTF-8">
  <title>Daclizumab</title>
  <meta name="viewport" content="width=device-width, initial-scale=1.0">
  <script>
    function importScript() { return 1 } // this is to avoid the error from site.js
  </script>
  <link rel="canonical" href="https://en.wikipedia.org/wiki/Daclizumab">
  <link href="../-/s/css_modules/ext.cite.ux-enhancements.css" tppabs="https://ptable.com/wiki/compounds/-/s/css_modules/ext.cite.ux-enhancements.css" rel="stylesheet" type="text/css" class="">
<link href="../-/s/css_modules/ext.cite.styles.css" tppabs="https://ptable.com/wiki/compounds/-/s/css_modules/ext.cite.styles.css" rel="stylesheet" type="text/css" class="">
<link href="../-/s/css_modules/fi000001.css" tppabs="https://ptable.com/wiki/compounds/-/s/css_modules/skins.minerva.base.reset|skins.minerva.content.styles|ext.cite.style|site.styles|mobile.app.pagestyles.android|mediawiki.page.gallery.styles|mediawiki.skinning.content.parsoid.css" rel="stylesheet" type="text/css" class="">
  <link href="../-/s/css_modules/style.css" tppabs="https://ptable.com/wiki/compounds/-/s/css_modules/style.css" rel="stylesheet" type="text/css" class=""><link href="../-/s/css_modules/content.parsoid.css" tppabs="https://ptable.com/wiki/compounds/-/s/css_modules/content.parsoid.css" rel="stylesheet" type="text/css" class=""><link href="../-/s/css_modules/inserted_style.css" tppabs="https://ptable.com/wiki/compounds/-/s/css_modules/inserted_style.css" rel="stylesheet" type="text/css" class="">
  <script src="../-/j/js_modules/script.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/script.js" class=""></script><script src="../-/j/js_modules/masonry.min.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/masonry.min.js" class=""></script><script src="../-/j/js_modules/article_list_home.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/article_list_home.js" class=""></script><script src="../-/j/js_modules/images_loaded.min.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/images_loaded.min.js" class=""></script><script src="../-/j/js_modules/node_module/details-element-polyfill/dist/details-element-polyfill.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/node_module/details-element-polyfill/dist/details-element-polyfill.js" class=""></script>
<link type="root" href=""></head>

<body class="mediawiki mw-hide-empty-elt ns-0 ns-subject stable skin-minerva action-view animations">
  <div id="mw-mf-viewport" class="feature-header-v2">
    <div id="mw-mf-page-center">
      <div id="content" class="mw-body">
        <a id="top"></a>
        <div id="bodyContent" class="content mw-parser-output">
          
          <div id="mw-content-text" style="direction: ltr;"><h1 class="section-heading" tabindex="0" aria-haspopup="true" data-section-id="0">
  <span class="mw-headline" id="title_0">Daclizumab</span>
</h1>
<div id="mf-section-0" class="mf-section-0" aria-pressed="true" aria-expanded="true">
  <p><b>Daclizumab</b> (trade name <b>Zinbryta</b>) is a therapeutic humanized monoclonal antibody which was used for the treatment of adults with relapsing forms of multiple sclerosis (MS). Daclizumab works by binding to CD25, the alpha subunit of the IL-2 receptor of T-cells.</p>

<table class="infobox" style="width:22em;border-spacing:2px;"><caption><span>Daclizumab</span></caption><tbody><tr><th colspan="2" style="text-align:center;background:#ddd">Monoclonal antibody</th></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Type</th><td>Whole antibody</td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Source</th><td>Humanized (from mouse)</td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Target</th><td>CD25</td></tr><tr><th colspan="2" style="text-align:center;background:#ddd">Clinical data</th></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Trade names</th><td>Zinbryta (multiple sclerosis)<br>Zenapax (acute transplant rejection, discontinued in 2009)</td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">AHFS/Drugs.com</th><td><span><a href="javascript:if(confirm('https://www.drugs.com/zinbryta.html  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.drugs.com/zinbryta.html'" tppabs="https://www.drugs.com/zinbryta.html" class="external text external">zinbryta</a></span></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">License data</th><td><div class="plainlist">
<ul><li><small><abbr class="country-name">EU</abbr></small><span>&nbsp;</span>EMA:<span>&nbsp;</span><span><a href="javascript:if(confirm('http://www.ema.europa.eu/ema/index.jsp?curl=%2Fpages%2Fmedicines%2Flanding%2Fepar_search.jsp&mid=&searchTab=searchByKey&alreadyLoaded=true&isNewQuery=true&status=Authorised&status=Withdrawn&status=Suspended&status=Refused&keywordSearch=Submit&searchType=inn&taxonomyPath=&treeNumber=&searchGenericType=generics&keyword=Daclizumab  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.ema.europa.eu/ema/index.jsp?curl=%2Fpages%2Fmedicines%2Flanding%2Fepar_search.jsp&mid=&searchTab=searchByKey&alreadyLoaded=true&isNewQuery=true&status=Authorised&status=Withdrawn&status=Suspended&status=Refused&keywordSearch=Submit&searchType=inn&taxonomyPath=&treeNumber=&searchGenericType=generics&keyword=Daclizumab'" tppabs="http://www.ema.europa.eu/ema/index.jsp?curl=%2Fpages%2Fmedicines%2Flanding%2Fepar_search.jsp&mid=&searchTab=searchByKey&alreadyLoaded=true&isNewQuery=true&status=Authorised&status=Withdrawn&status=Suspended&status=Refused&keywordSearch=Submit&searchType=inn&taxonomyPath=&treeNumber=&searchGenericType=generics&keyword=Daclizumab" class="external text external">by INN</a></span></li></ul></div>
</td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Pregnancy<br>category</th><td><div class="plainlist">
<ul><li><small><abbr class="country-name">AU</abbr>:</small><span> </span>B3<span> </span></li>
<li><small><abbr class="country-name">US</abbr>:</small><span> </span>C (Risk not ruled out)<span> </span></li></ul>

<ul></ul>
</div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Routes of<br>administration</th><td>Subcutaneous injection (MS)<br>Intravenous (transplant rejection, discontinued)</td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">ATC code</th><td><div class="plainlist"><ul><li>L04AC01<span> </span>(<span><a href="javascript:if(confirm('https://www.whocc.no/atc_ddd_index/?code=L04AC01  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.whocc.no/atc_ddd_index/?code=L04AC01'" tppabs="https://www.whocc.no/atc_ddd_index/?code=L04AC01" class="external text external">WHO</a></span>)<span> </span></li></ul></div></td></tr><tr><th colspan="2" style="text-align:center;background:#ddd">Legal status</th></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Legal status</th><td><div class="plainlist">
<ul><li><small><abbr class="country-name">AU</abbr>:</small><span> </span>S4 (Prescription only)<span> </span></li>
<li><small><abbr class="country-name">US</abbr>:</small><span> </span>℞-only<span> </span>/<span>&nbsp;</span>Withdrawn<span class="mw-ref" id="cite_ref-FDA_PR_1-0"><a href="#cite_note-FDA_PR-1" style="counter-reset: mw-Ref 1;"><span class="mw-reflink-text">[1]</span></a></span></li>
<li>In<span>&nbsp;</span>general: ℞<span>&nbsp;</span>(Prescription only)</li></ul></div>
</td></tr><tr><th colspan="2" style="text-align:center;background:#ddd">Pharmacokinetic data</th></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Bioavailability</th><td>90%</td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Metabolism</th><td>Proteases</td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Elimination <span class="nowrap">half-life</span></th><td>21 days (11–38 days)</td></tr><tr><th colspan="2" style="text-align:center;background:#ddd">Identifiers</th></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">CAS Number</th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('http://www.commonchemistry.org/ChemicalDetail.aspx?ref=152923-56-3  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.commonchemistry.org/ChemicalDetail.aspx?ref=152923-56-3'" tppabs="http://www.commonchemistry.org/ChemicalDetail.aspx?ref=152923-56-3" class="external text external">152923-56-3</a></span><sup><span>&nbsp;</span><figure-inline><span><img src="../I/m/Yes_check.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/Yes_check.svg.png" data-file-width="600" data-file-height="600" data-file-type="drawing" height="7" width="7"></span></figure-inline><span style="display:none">Y</span></sup></li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">DrugBank</th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('https://www.drugbank.ca/drugs/DB00111  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.drugbank.ca/drugs/DB00111'" tppabs="https://www.drugbank.ca/drugs/DB00111" class="external text external">DB00111</a></span><sup><span>&nbsp;</span><figure-inline><span><img src="../I/m/Yes_check.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/Yes_check.svg.png" data-file-width="600" data-file-height="600" data-file-type="drawing" height="7" width="7"></span></figure-inline><span style="display:none">Y</span></sup></li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">ChemSpider</th><td><div class="plainlist"><ul><li>none</li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">UNII</th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('https://fdasis.nlm.nih.gov/srs/srsdirect.jsp?regno=CUJ2MVI71Y  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://fdasis.nlm.nih.gov/srs/srsdirect.jsp?regno=CUJ2MVI71Y'" tppabs="https://fdasis.nlm.nih.gov/srs/srsdirect.jsp?regno=CUJ2MVI71Y" class="external text external">CUJ2MVI71Y</a></span></li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">KEGG</th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('https://www.kegg.jp/entry/D03639  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.kegg.jp/entry/D03639'" tppabs="https://www.kegg.jp/entry/D03639" class="external text external">D03639</a></span><sup><span>&nbsp;</span><figure-inline><span><img src="../I/m/X_mark.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/X_mark.svg.png" data-file-width="525" data-file-height="600" data-file-type="drawing" height="8" width="7"></span></figure-inline><span style="display:none">N</span></sup></li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">ChEMBL</th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('https://www.ebi.ac.uk/chembldb/index.php/compound/inspect/ChEMBL1201605  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ebi.ac.uk/chembldb/index.php/compound/inspect/ChEMBL1201605'" tppabs="https://www.ebi.ac.uk/chembldb/index.php/compound/inspect/ChEMBL1201605" class="external text external">ChEMBL1201605</a></span><sup><span>&nbsp;</span><figure-inline><span><img src="../I/m/X_mark.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/X_mark.svg.png" data-file-width="525" data-file-height="600" data-file-type="drawing" height="8" width="7"></span></figure-inline><span style="display:none">N</span></sup></li></ul></div></td></tr><tr><th colspan="2" style="text-align:center;background:#ddd">Chemical and physical data</th></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Formula</th><td><span>C</span><sub>6332</sub><span>H</span><sub>9808</sub><span>N</span><sub>1678</sub><span>O</span><sub>1989</sub><span>S</span><sub>42</sub></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Molar mass</th><td><span class="nowrap">142<span style="margin-left:.25em;">612</span>.39</span><span>&nbsp;</span>g·mol<sup>−1</sup></td></tr><tr><td colspan="2" style="text-align:center"><style data-mw-deduplicate="TemplateStyles:r886047488">.mw-parser-output .nobold{font-weight:normal}</style><span class="nobold"><span>&nbsp;</span><sup><figure-inline><span><img src="../I/m/X_mark.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/X_mark.svg.png" data-file-width="525" data-file-height="600" data-file-type="drawing" height="8" width="7"></span></figure-inline><span style="display:none">N</span><figure-inline><span><img src="../I/m/Yes_check.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/Yes_check.svg.png" data-file-width="600" data-file-height="600" data-file-type="drawing" height="7" width="7"></span></figure-inline><span style="display:none">Y</span></sup><span>&nbsp;</span>(what is this?)</span><span class="nobold"><span>&nbsp;</span><span>&nbsp;</span><span class="reflink  nourlexpansion"><a href="javascript:if(confirm('https://en.wikipedia.org/w/index.php?title=Special:ComparePages&rev1=458621431&page2=Daclizumab  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://en.wikipedia.org/w/index.php?title=Special:ComparePages&rev1=458621431&page2=Daclizumab'" tppabs="https://en.wikipedia.org/w/index.php?title=Special:ComparePages&rev1=458621431&page2=Daclizumab" class="external text external">(verify)</a></span></span></td></tr></tbody></table>
<p>In March 2018, it was voluntarily withdrawn from the market by Biogen and Abbvie after reports of encephalitis in Europe.<span class="mw-ref" id="cite_ref-2"><a href="#cite_note-2" style="counter-reset: mw-Ref 2;"><span class="mw-reflink-text">[2]</span></a></span><span class="mw-ref" id="cite_ref-3"><a href="#cite_note-3" style="counter-reset: mw-Ref 3;"><span class="mw-reflink-text">[3]</span></a></span><span class="mw-ref" id="cite_ref-FDA_PR_1-1"><a href="#cite_note-FDA_PR-1" style="counter-reset: mw-Ref 1;"><span class="mw-reflink-text">[1]</span></a></span></p>


</div><details data-level="2" open="">
    <summary class="section-heading"><h2 id="Medical_uses">Medical uses</h2></summary>
    
<p>Daclizumab was used to treat adults with relapsing forms of multiple sclerosis.<span class="mw-ref" id="cite_ref-BLAapproval_4-0"><a href="#cite_note-BLAapproval-4" style="counter-reset: mw-Ref 4;"><span class="mw-reflink-text">[4]</span></a></span> It is administered subcutaneously.<span class="mw-ref" id="cite_ref-2015rev_5-0"><a href="#cite_note-2015rev-5" style="counter-reset: mw-Ref 5;"><span class="mw-reflink-text">[5]</span></a></span></p>

<p>In clinical trials, decreases of 45% in annualized relapse rate have been reported, as well as a 41% reduction in the proportion of patients who relapsed, and a 54% reduction in the number of new lesions<span class="mw-ref" id="cite_ref-2015rev_5-1"><a href="#cite_note-2015rev-5" style="counter-reset: mw-Ref 5;"><span class="mw-reflink-text">[5]</span></a></span>. A 2013 Cochrane systematic review concluded that there was insufficient evidence to determine the efficacy of daclizumab relative to placebo in people with relapsing-remitting MS and, prior to its being discontinued, the need to investigate longer lengths of treatment and follow-up.<span class="mw-ref" id="cite_ref-6"><a href="#cite_note-6" style="counter-reset: mw-Ref 6;"><span class="mw-reflink-text">[6]</span></a></span></p>


    <details data-level="3" open="">
    <summary class="section-heading"><h3 id="Discontinued_use">Discontinued use</h3></summary>
    
<p>Daclizumab was approved and used to prevent acute rejection of kidney transplant, along with cyclosporine and corticosteroids.<span class="mw-ref" id="cite_ref-RejectionLabel_7-0"><a href="#cite_note-RejectionLabel-7" style="counter-reset: mw-Ref 7;"><span class="mw-reflink-text">[7]</span></a></span>  For that indication, side effects with a frequency of at least 10% included sleeplessness, tremor, headache, arterial hypertension, dyspnoea, gastrointestinal side effects and oedema. In rare cases, the drug could cause severe anaphylaxis.<span class="mw-ref" id="cite_ref-EPAR_8-0"><a href="#cite_note-EPAR-8" style="counter-reset: mw-Ref 8;"><span class="mw-reflink-text">[8]</span></a></span></p>


</details>

</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="Contraindications">Contraindications</h2></summary>
    
<p>In the US, daclizumab is contraindicated in people with liver impairment, including significantly elevated liver enzymes (ALT, AST) and autoimmune hepatitis.<span class="mw-ref" id="cite_ref-9"><a href="#cite_note-9" style="counter-reset: mw-Ref 9;"><span class="mw-reflink-text">[9]</span></a></span></p> 

<p>The European Medicines Agency (EMA) originally approved the drug without any contraindications apart from known hypersensitivity,<span class="mw-ref" id="cite_ref-AC_10-0"><a href="#cite_note-AC-10" style="counter-reset: mw-Ref 10;"><span class="mw-reflink-text">[10]</span></a></span> but required Biogen to implement a hepatic risk management guide for physicians.<span class="mw-ref" id="cite_ref-11"><a href="#cite_note-11" style="counter-reset: mw-Ref 11;"><span class="mw-reflink-text">[11]</span></a></span> In July 2017, the EMA has issued a provisional contraindication for patients with pre-existing liver disease or liver impairment.<span class="mw-ref" id="cite_ref-12"><a href="#cite_note-12" style="counter-reset: mw-Ref 12;"><span class="mw-reflink-text">[12]</span></a></span>  The marketing authorisation was withdrawn in the EU on 27 March 2018. An EMA review concluded that the medicine poses a risk of serious and potentially fatal immune reactions affecting the brain, liver and other organs.<span class="mw-ref" id="cite_ref-13"><a href="#cite_note-13" style="counter-reset: mw-Ref 13;"><span class="mw-reflink-text">[13]</span></a></span></p>


    
</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="Adverse_effects">Adverse effects</h2></summary>
    
<p>In clinical trials for MS, there were no treatment-related deaths or increased risk of cancer; side effects that occurred more frequently with daclizumab versus interferon included infections (65% versus 57%), skin rashes (37% versus 19%) and liver complications  (approximately 18% versus 12%).<span class="mw-ref" id="cite_ref-2015rev_5-2"><a href="#cite_note-2015rev-5" style="counter-reset: mw-Ref 5;"><span class="mw-reflink-text">[5]</span></a></span></p>


    
</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="Interactions">Interactions</h2></summary>
    

<p>As an antibody, daclizumab is expected to have a very low potential for pharmacokinetic interactions with other drugs.<span class="mw-ref" id="cite_ref-AC_10-1"><a href="#cite_note-AC-10" style="counter-reset: mw-Ref 10;"><span class="mw-reflink-text">[10]</span></a></span></p>


    
</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="Pharmacology">Pharmacology</h2></summary>
    

    <details data-level="3" open="">
    <summary class="section-heading"><h3 id="Mechanism_of_action">Mechanism of action</h3></summary>
    
<p>Daclizumab blocks IL-2 receptors containing the alpha subunit (CD25), which include the high-affinity receptors. Medium-affinity receptors, on the other hand, consist of two beta subunits (CD122) and are not affected by daclizumab. While the exact mechanism is unknown, the net effect is a reduction of T-cell responses and expansion of CD56<sup>bright</sup> natural killer cells.<span class="mw-ref" id="cite_ref-AC_10-2"><a href="#cite_note-AC-10" style="counter-reset: mw-Ref 10;"><span class="mw-reflink-text">[10]</span></a></span></p>


</details>
<details data-level="3" open="">
    <summary class="section-heading"><h3 id="Pharmacokinetics">Pharmacokinetics</h3></summary>
    
<p>After subcutaneous injection of a single dose, daclizumab has a bioavailability of about 90% and reaches highest blood plasma levels after 5 to 7 days. Given every four weeks, steady state concentrations are found after the fourth dose. It is expected that daclizumab, like other antibodies, is degraded by proteases to peptides and finally amino acids, and that it does not interact with cytochrome P450 liver enzymes.<span class="mw-ref" id="cite_ref-AC_10-3"><a href="#cite_note-AC-10" style="counter-reset: mw-Ref 10;"><span class="mw-reflink-text">[10]</span></a></span></p>

<p>The biological half-life is 21 days. Patients who developed antibodies against daclizumab eliminated it 19% faster.<span class="mw-ref" id="cite_ref-AC_10-4"><a href="#cite_note-AC-10" style="counter-reset: mw-Ref 10;"><span class="mw-reflink-text">[10]</span></a></span></p>


</details>

</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="History">History</h2></summary>
    
<p>Daclizumab was created by scientists at PDL BioPharma (called "Protein Design Labs" at that time) by humanizing the mouse mAb called anti-Tac, which targets CD25, the IL-2 receptor α chain; it blocks the interaction of <a href="Interleukin_2.htm" tppabs="https://ptable.com/wiki/compounds/A/Interleukin_2" title="Interleukin 2">IL-2</a> with the IL-2 receptor and prevents activation of T cells.<span class="mw-ref" id="cite_ref-14"><a href="#cite_note-14" style="counter-reset: mw-Ref 14;"><span class="mw-reflink-text">[14]</span></a></span> Anti-Tac had been discovered by Thomas A. Waldmann, M.D., chief of the Metabolism Branch at the National Cancer Institute and his team, and they had conducted animal studies and a small clinical trial of anti-Tac in people with T-cell leukemia, with promising results, but people quickly developed their own antibodies rejecting the mouse protein; Waldman, and his colleagues then approached Protein Design Labs to humanize the antibody.<span class="mw-ref" id="cite_ref-JNCI_15-0"><a href="#cite_note-JNCI-15" style="counter-reset: mw-Ref 15;"><span class="mw-reflink-text">[15]</span></a></span>  PDL and the NIH scientists then approached Roche, a leader in transplant medicine development, to get the drug developed and approved, as PDL didn't have the resources to actually bring the product to market.<span class="mw-ref" id="cite_ref-JNCI_15-1"><a href="#cite_note-JNCI-15" style="counter-reset: mw-Ref 15;"><span class="mw-reflink-text">[15]</span></a></span> In March 2018 the drug was removed from the market worldwide</p>

<p>In December 1997 daclizumab was approved by the FDA for use in preventing acute rejection of kidney transplants, in combination with ciclosporin and corticosteroids; it was the first humanized antibody approved anywhere in the world.<span class="mw-ref" id="cite_ref-16"><a href="#cite_note-16" style="counter-reset: mw-Ref 16;"><span class="mw-reflink-text">[16]</span></a></span><span class="mw-ref" id="cite_ref-PLfirst_17-0"><a href="#cite_note-PLfirst-17" style="counter-reset: mw-Ref 17;"><span class="mw-reflink-text">[17]</span></a></span>  At launch, the average wholesale price for the drug was estimated to be $6,800 for five doses and it was estimated that annual sales would be between $100 million and $250 million within five years of the launch and it was thought that the drug's use would be expanded for use in other organ transplants.<span class="mw-ref" id="cite_ref-PLfirst_17-1"><a href="#cite_note-PLfirst-17" style="counter-reset: mw-Ref 17;"><span class="mw-reflink-text">[17]</span></a></span>  It was approved in Europe in 1999.<span class="mw-ref" id="cite_ref-18"><a href="#cite_note-18" style="counter-reset: mw-Ref 18;"><span class="mw-reflink-text">[18]</span></a></span></p>

<p>PDL began clinical trials of daclizumab on its own, and in September 2004 after the drug had shown promise in a Phase II trial, PDL and Roche agreed to expand their relationship to include codevelopment of daclizumab for asthma and other respiratory conditions.<span class="mw-ref" id="cite_ref-19"><a href="#cite_note-19" style="counter-reset: mw-Ref 19;"><span class="mw-reflink-text">[19]</span></a></span>  In August 2005, PDL and Biogen Idec agreed to collaborate to develop daclizumab in indications outside the fields of organ rejection and respiratory disease.<span class="mw-ref" id="cite_ref-pmid16211058_20-0"><a href="#cite_note-pmid16211058-20" style="counter-reset: mw-Ref 20;"><span class="mw-reflink-text">[20]</span></a></span>  In November 2005 Roche and PDL agreed to try to develop a formulation of daclizumab that would be useful as a subcutaneous injection for longterm maintenance in organ transplant.<span class="mw-ref" id="cite_ref-21"><a href="#cite_note-21" style="counter-reset: mw-Ref 21;"><span class="mw-reflink-text">[21]</span></a></span>  The next year Roche and PDL announced that the collaboration for all indications was ending,<span class="mw-ref" id="cite_ref-22"><a href="#cite_note-22" style="counter-reset: mw-Ref 22;"><span class="mw-reflink-text">[22]</span></a></span> and in 2009 it announced that it was discontinuing Zenapax worldwide "in view of available alternative treatments and the diminishing market demand" and "not due to any safety issue."<span class="mw-ref" id="cite_ref-23"><a href="#cite_note-23" style="counter-reset: mw-Ref 23;"><span class="mw-reflink-text">[23]</span></a></span><span class="mw-ref" id="cite_ref-24"><a href="#cite_note-24" style="counter-reset: mw-Ref 24;"><span class="mw-reflink-text">[24]</span></a></span></p>

<p>in 2008 PDL spun out its active development programs into a company called Facet Biotech and development of daclizumab for multiple sclerosis and the partnership with Biogen was included in that spinout.<span class="mw-ref" id="cite_ref-25"><a href="#cite_note-25" style="counter-reset: mw-Ref 25;"><span class="mw-reflink-text">[25]</span></a></span><span class="mw-ref" id="cite_ref-2008sec_26-0"><a href="#cite_note-2008sec-26" style="counter-reset: mw-Ref 26;"><span class="mw-reflink-text">[26]</span></a></span>  In 2009 Biogen attempted a hostile buy out of Facet for $350M;<span class="mw-ref" id="cite_ref-27"><a href="#cite_note-27" style="counter-reset: mw-Ref 27;"><span class="mw-reflink-text">[27]</span></a></span> Facet rejected that offer and was purchased by Abbvie for $450 million in cash the next year.<span class="mw-ref" id="cite_ref-28"><a href="#cite_note-28" style="counter-reset: mw-Ref 28;"><span class="mw-reflink-text">[28]</span></a></span>  In May 2016 the FDA approved daclizumab for the treatment of relapsing multiple sclerosis in adults in 2016 under the trade name Zinbryta, with requirements for postmarketing studies and to submit a formal Risk Evaluation and Mitigation Strategy.<span class="mw-ref" id="cite_ref-BLAapproval_4-1"><a href="#cite_note-BLAapproval-4" style="counter-reset: mw-Ref 4;"><span class="mw-reflink-text">[4]</span></a></span><span class="mw-ref" id="cite_ref-29"><a href="#cite_note-29" style="counter-reset: mw-Ref 29;"><span class="mw-reflink-text">[29]</span></a></span></p>


    
</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="Research">Research</h2></summary>
    
<p>Daclizumab has been studied in a small clinical trial of people with  birdshot chorioretinopathy.<span class="mw-ref" id="cite_ref-pmid18268208_30-0"><a href="#cite_note-pmid18268208-30" style="counter-reset: mw-Ref 30;"><span class="mw-reflink-text">[30]</span></a></span></p>


    
</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="References">References</h2></summary>
    
<div class="reflist columns references-column-width" style="-moz-column-width: 30em; -webkit-column-width: 30em; column-width: 30em; list-style-type: decimal;">
<ol class="mw-references references"><li id="cite_note-FDA_PR-1"> <span id="mw-reference-text-cite_note-FDA_PR-1" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://www.fda.gov/drugs/drug-safety-and-availability/fda-working-manufacturers-withdraw-zinbryta-market-united-states  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.fda.gov/drugs/drug-safety-and-availability/fda-working-manufacturers-withdraw-zinbryta-market-united-states'" tppabs="https://www.fda.gov/drugs/drug-safety-and-availability/fda-working-manufacturers-withdraw-zinbryta-market-united-states" class="external text external">"FDA working with manufacturers to withdraw Zinbryta from the market in the United States"</a>. <i>U.S. Food and Drug Administration (FDA)</i><span class="reference-accessdate">. Retrieved <span class="nowrap">15 March</span> 2018</span>.</cite></span></li><li id="cite_note-2"> <span id="mw-reference-text-cite_note-2" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://www.reuters.com/article/us-biogen-zinbryta/biogen-abbvie-withdraw-multiple-sclerosis-drug-zinbryta-idUSKCN1GE1BV  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.reuters.com/article/us-biogen-zinbryta/biogen-abbvie-withdraw-multiple-sclerosis-drug-zinbryta-idUSKCN1GE1BV'" tppabs="https://www.reuters.com/article/us-biogen-zinbryta/biogen-abbvie-withdraw-multiple-sclerosis-drug-zinbryta-idUSKCN1GE1BV" class="external text external">"Biogen, AbbVie withdraw multiple sclerosis drug Zinbryta"</a>. <i>Reuters</i>. 2018.</cite></span></li><li id="cite_note-3"> <span id="mw-reference-text-cite_note-3" class="mw-reference-text"><cite id="CITEREFLoftus2018" class="citation web cs1">Loftus, Peter (2 March 2018). <a href="javascript:if(confirm('https://www.wsj.com/articles/biogen-and-abbvie-take-multiple-sclerosis-drug-off-market-1520007411  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.wsj.com/articles/biogen-and-abbvie-take-multiple-sclerosis-drug-off-market-1520007411'" tppabs="https://www.wsj.com/articles/biogen-and-abbvie-take-multiple-sclerosis-drug-off-market-1520007411" class="external text external">"Biogen and Abbvie Take Multiple Sclerosis Drug Off Market"</a>. <i>The Wall Street Journal</i>.</cite></span></li><li id="cite_note-BLAapproval-4"> <span id="mw-reference-text-cite_note-BLAapproval-4" class="mw-reference-text">FDA <a href="javascript:if(confirm('http://www.accessdata.fda.gov/drugsatfda_docs/appletter/2016/761029Orig1s000ltr.pdf  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.accessdata.fda.gov/drugsatfda_docs/appletter/2016/761029Orig1s000ltr.pdf'" tppabs="http://www.accessdata.fda.gov/drugsatfda_docs/appletter/2016/761029Orig1s000ltr.pdf" class="external text external">BLA Approval letter</a> May 27, 2016</span></li><li id="cite_note-2015rev-5"> <span id="mw-reference-text-cite_note-2015rev-5" class="mw-reference-text"><cite id="CITEREFLycke2015" class="citation journal cs1">Lycke J (November 2015). <a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4643868  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4643868'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4643868" class="external text external">"Monoclonal antibody therapies for the treatment of relapsing-remitting multiple sclerosis: differentiating mechanisms and clinical outcomes"</a>. <i>Therapeutic Advances in Neurological Disorders</i>. <b>8</b> (6): 274–93. doi:<a href="javascript:if(confirm('https://doi.org/10.1177%2F1756285615605429  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1177%2F1756285615605429'" tppabs="https://doi.org/10.1177%2F1756285615605429" class="external text external">10.1177/1756285615605429</a>. PMC<span>&nbsp;</span><span class="cs1-lock-free"><a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4643868  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4643868'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4643868" class="external text external">4643868</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/26600872  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/26600872'" tppabs="https://pubmed.ncbi.nlm.nih.gov/26600872" class="external text external">26600872</a>.</cite></span></li><li id="cite_note-6"> <span id="mw-reference-text-cite_note-6" class="mw-reference-text"><cite id="CITEREFLiuWangZhanXia2013" class="citation journal cs1">Liu, Jia; Wang, Lu-Ning; Zhan, Siyan; Xia, Yinyin (2013-12-23). "Daclizumab for relapsing remitting multiple sclerosis". <i>The Cochrane Database of Systematic Reviews</i> (12): CD008127. doi:<a href="javascript:if(confirm('https://doi.org/10.1002%2F14651858.CD008127.pub4  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1002%2F14651858.CD008127.pub4'" tppabs="https://doi.org/10.1002%2F14651858.CD008127.pub4" class="external text external">10.1002/14651858.CD008127.pub4</a>. ISSN<span>&nbsp;</span><a href="javascript:if(confirm('https://www.worldcat.org/issn/1469-493X  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.worldcat.org/issn/1469-493X'" tppabs="https://www.worldcat.org/issn/1469-493X" class="external text external">1469-493X</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/24363032  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/24363032'" tppabs="https://pubmed.ncbi.nlm.nih.gov/24363032" class="external text external">24363032</a>.</cite></span></li><li id="cite_note-RejectionLabel-7"> <span id="mw-reference-text-cite_note-RejectionLabel-7" class="mw-reference-text"><a href="javascript:if(confirm('http://www.accessdata.fda.gov/drugsatfda_docs/label/2005/103749s5059lbl.pdf  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.accessdata.fda.gov/drugsatfda_docs/label/2005/103749s5059lbl.pdf'" tppabs="http://www.accessdata.fda.gov/drugsatfda_docs/label/2005/103749s5059lbl.pdf" class="external text external">Rejection label</a> Supplement label update September 2005</span></li><li id="cite_note-EPAR-8"> <span id="mw-reference-text-cite_note-EPAR-8" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('http://www.emea.europa.eu/docs/en_GB/document_library/EPAR_-_Summary_for_the_public/human/000198/WC500057570.pdf  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.emea.europa.eu/docs/en_GB/document_library/EPAR_-_Summary_for_the_public/human/000198/WC500057570.pdf'" tppabs="http://www.emea.europa.eu/docs/en_GB/document_library/EPAR_-_Summary_for_the_public/human/000198/WC500057570.pdf" class="external text external">"EPAR for Zenapax"</a> <span class="cs1-format">(PDF)</span>. European Medicines Agency. 2007.</cite></span></li><li id="cite_note-9"> <span id="mw-reference-text-cite_note-9" class="mw-reference-text"><span><a href="javascript:if(confirm('https://www.drugs.com/pro/zinbryta.html  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.drugs.com/pro/zinbryta.html'" tppabs="https://www.drugs.com/pro/zinbryta.html" class="external text external">FDA Professional Drug Information</a></span> for Zinbryta.</span></li><li id="cite_note-AC-10"> <span id="mw-reference-text-cite_note-AC-10" class="mw-reference-text"><cite id="CITEREFHaberfeld,_H2016" class="citation book cs1">Haberfeld, H, ed. (2016). <i>Austria-Codex</i> (in German). Vienna: Österreichischer Apothekerverlag.</cite></span></li><li id="cite_note-11"> <span id="mw-reference-text-cite_note-11" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/003862/WC500210598.pdf  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/003862/WC500210598.pdf'" tppabs="http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/003862/WC500210598.pdf" class="external text external">"Zinbryta Summary of Product Characteristics"</a> <span class="cs1-format">(PDF)</span>. European Medicines Agency. 2016.</cite></span></li><li id="cite_note-12"> <span id="mw-reference-text-cite_note-12" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('http://www.ema.europa.eu/docs/en_GB/document_library/Referrals_document/Zinbryta_20/Under_evaluation/WC500230924.pdf  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.ema.europa.eu/docs/en_GB/document_library/Referrals_document/Zinbryta_20/Under_evaluation/WC500230924.pdf'" tppabs="http://www.ema.europa.eu/docs/en_GB/document_library/Referrals_document/Zinbryta_20/Under_evaluation/WC500230924.pdf" class="external text external">"Zinbryta Article-20 referral - Summary of provisional measures"</a> <span class="cs1-format">(PDF)</span>. European Medicines Agency. 20 July 2017.</cite></span></li><li id="cite_note-13"> <span id="mw-reference-text-cite_note-13" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://www.ema.europa.eu/en/medicines/human/referrals/zinbryta  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ema.europa.eu/en/medicines/human/referrals/zinbryta'" tppabs="https://www.ema.europa.eu/en/medicines/human/referrals/zinbryta" class="external text external">"EMA review of Zinbryta confirms medicine's risks outweigh its benefits"</a>. <i>European Medicines Agency</i>. 27 March 2018.</cite></span></li><li id="cite_note-14"> <span id="mw-reference-text-cite_note-14" class="mw-reference-text"><cite id="CITEREFTsurushitaHintonKumar2005" class="citation journal cs1">Tsurushita N, Hinton PR, Kumar S (May 2005). "Design of humanized antibodies: from anti-Tac to Zenapax". <i>Methods</i>. <b>36</b> (1): 69–83. doi:<a href="javascript:if(confirm('https://doi.org/10.1016%2Fj.ymeth.2005.01.007  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2Fj.ymeth.2005.01.007'" tppabs="https://doi.org/10.1016%2Fj.ymeth.2005.01.007" class="external text external">10.1016/j.ymeth.2005.01.007</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/15848076  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/15848076'" tppabs="https://pubmed.ncbi.nlm.nih.gov/15848076" class="external text external">15848076</a>.</cite></span></li><li id="cite_note-JNCI-15"> <span id="mw-reference-text-cite_note-JNCI-15" class="mw-reference-text"><cite id="CITEREFSwensonWeisingerRuggeriReaven1975" class="citation journal cs1">Swenson RS, Weisinger JR, Ruggeri JL, Reaven GM (February 1975). "Evidence that parathyroid hormone is not required for phosphate homeostasis in renal failure". <i>Metabolism</i>. <b>24</b> (2): 199–204. doi:<a href="javascript:if(confirm('https://doi.org/10.1016%2F0026-0495%2875%2990021-9  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2F0026-0495%2875%2990021-9'" tppabs="https://doi.org/10.1016%2F0026-0495%2875%2990021-9" class="external text external">10.1016/0026-0495(75)90021-9</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/1113683  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/1113683'" tppabs="https://pubmed.ncbi.nlm.nih.gov/1113683" class="external text external">1113683</a>.</cite></span></li><li id="cite_note-16"> <span id="mw-reference-text-cite_note-16" class="mw-reference-text">Lawrence M. Fisher for The New York Times. December 12, 1997 <a href="javascript:if(confirm('https://www.nytimes.com/1997/12/12/us/genetically-engineered-drug-approved-for-kidney-transplants.html  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.nytimes.com/1997/12/12/us/genetically-engineered-drug-approved-for-kidney-transplants.html'" tppabs="https://www.nytimes.com/1997/12/12/us/genetically-engineered-drug-approved-for-kidney-transplants.html" class="external text external">Genetically Engineered Drug Approved for Kidney Transplants</a></span></li><li id="cite_note-PLfirst-17"> <span id="mw-reference-text-cite_note-PLfirst-17" class="mw-reference-text">Staff, The Pharma Letter. December 17, 1997. <a href="javascript:if(confirm('http://www.thepharmaletter.com/article/roche-s-zenapax-gets-first-approval-for-transplants  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.thepharmaletter.com/article/roche-s-zenapax-gets-first-approval-for-transplants'" tppabs="http://www.thepharmaletter.com/article/roche-s-zenapax-gets-first-approval-for-transplants" class="external text external">Roche's Zenapax Gets First Approval For Transplants</a></span></li><li id="cite_note-18"> <span id="mw-reference-text-cite_note-18" class="mw-reference-text">Roche. March 04, 1999 <a href="javascript:if(confirm('http://www.evaluategroup.com/Universal/View.aspx?type=Story&id=7568  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.evaluategroup.com/Universal/View.aspx?type=Story&id=7568'" tppabs="http://www.evaluategroup.com/Universal/View.aspx?type=Story&id=7568" class="external text external">Roche Press Release:  Zenapax (daclizumab), The First Humanized Monoclonal Antibody To Prevent Organ Rejection, Approved In The European Union</a></span></li><li id="cite_note-19"> <span id="mw-reference-text-cite_note-19" class="mw-reference-text">Candace Hoffmann for First Word Pharma. September 16, 2004  <a href="javascript:if(confirm('http://www.firstwordpharma.com/node/217798?tsid=17  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.firstwordpharma.com/node/217798?tsid=17#axzz4AHJfVHyr'" tppabs="http://www.firstwordpharma.com/node/217798?tsid=17#axzz4AHJfVHyr" class="external text external">Roche in new deal to co-development asthma drug</a></span></li><li id="cite_note-pmid16211058-20"> <span id="mw-reference-text-cite_note-pmid16211058-20" class="mw-reference-text"><cite id="CITEREFThiel2005" class="citation journal cs1">Thiel KA (October 2005). "A very firm handshake: biotech's growing negotiating power". <i>Nature Biotechnology</i>. <b>23</b> (10): 1221–6. doi:<a href="javascript:if(confirm('https://doi.org/10.1038%2Fnbt1005-1221  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1038%2Fnbt1005-1221'" tppabs="https://doi.org/10.1038%2Fnbt1005-1221" class="external text external">10.1038/nbt1005-1221</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/16211058  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/16211058'" tppabs="https://pubmed.ncbi.nlm.nih.gov/16211058" class="external text external">16211058</a>.</cite></span></li><li id="cite_note-21"> <span id="mw-reference-text-cite_note-21" class="mw-reference-text">Staff, PharmaTimes. November 1, 2005 <a href="javascript:if(confirm('http://www.pharmatimes.com/news/roche_inks_new_deal_for_transplant_drug_997651  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.pharmatimes.com/news/roche_inks_new_deal_for_transplant_drug_997651'" tppabs="http://www.pharmatimes.com/news/roche_inks_new_deal_for_transplant_drug_997651" class="external text external">Roche inks new deal for transplant drug</a></span></li><li id="cite_note-22"> <span id="mw-reference-text-cite_note-22" class="mw-reference-text">PharmaTimes  November 23, 2006 <a href="javascript:if(confirm('http://www.pharmatimes.com/news/roche_ducks_out_of_transplant_drug_alliance_995643  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.pharmatimes.com/news/roche_ducks_out_of_transplant_drug_alliance_995643'" tppabs="http://www.pharmatimes.com/news/roche_ducks_out_of_transplant_drug_alliance_995643" class="external text external">Roche ducks out of transplant drug alliance</a></span></li><li id="cite_note-23"> <span id="mw-reference-text-cite_note-23" class="mw-reference-text"><a href="javascript:if(confirm('http://www.ema.europa.eu/humandocs/PDFs/EPAR/Zenapax/68376508en.pdf  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.ema.europa.eu/humandocs/PDFs/EPAR/Zenapax/68376508en.pdf'" tppabs="http://www.ema.europa.eu/humandocs/PDFs/EPAR/Zenapax/68376508en.pdf" class="external text external">EMEA: Withdrawal of the marketing authorisation in the European Union</a></span></li><li id="cite_note-24"> <span id="mw-reference-text-cite_note-24" class="mw-reference-text">Roche via the FDA <a href="javascript:if(confirm('https://www.fda.gov/downloads/Drugs/DrugSafety/DrugShortages/UCM194907.pdf  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.fda.gov/downloads/Drugs/DrugSafety/DrugShortages/UCM194907.pdf'" tppabs="https://www.fda.gov/downloads/Drugs/DrugSafety/DrugShortages/UCM194907.pdf" class="external text external">Letter to  Healthcare Professionals</a> September 2009</span></li><li id="cite_note-25"> <span id="mw-reference-text-cite_note-25" class="mw-reference-text">John Carroll for FierceBiotech. 2009 <a href="javascript:if(confirm('http://www.fiercebiotech.com/special-report/emerging-drug-developer-facet-biotech  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.fiercebiotech.com/special-report/emerging-drug-developer-facet-biotech'" tppabs="http://www.fiercebiotech.com/special-report/emerging-drug-developer-facet-biotech" class="external text external">Emerging Drug Developer: Facet Biotech</a></span></li><li id="cite_note-2008sec-26"> <span id="mw-reference-text-cite_note-2008sec-26" class="mw-reference-text"><a href="javascript:if(confirm('https://www.sec.gov/Archives/edgar/data/882104/000110465908078237/a08-30875_18k.htm  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.sec.gov/Archives/edgar/data/882104/000110465908078237/a08-30875_18k.htm'" tppabs="https://www.sec.gov/Archives/edgar/data/882104/000110465908078237/a08-30875_18k.htm" class="external text external">PDL BioPharma, Inc. Form 8-K</a> December 17, 2008</span></li><li id="cite_note-27"> <span id="mw-reference-text-cite_note-27" class="mw-reference-text">Luke Timmerman for Xconomy. September 4, 2009 <a href="javascript:if(confirm('http://www.xconomy.com/boston/2009/09/04/biogen-idec-makes-hostile-350m-takeover-bid-for-facet-biotech/  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.xconomy.com/boston/2009/09/04/biogen-idec-makes-hostile-350m-takeover-bid-for-facet-biotech/'" tppabs="http://www.xconomy.com/boston/2009/09/04/biogen-idec-makes-hostile-350m-takeover-bid-for-facet-biotech/" class="external text external">Biogen Idec Makes Hostile $350M Takeover Bid for Facet Biotech</a></span></li><li id="cite_note-28"> <span id="mw-reference-text-cite_note-28" class="mw-reference-text">Staff, New York Times Dealbook.  March 9, 2010. <a href="javascript:if(confirm('https://dealbook.nytimes.com/2010/03/09/abbott-to-buy-facet-biotech-for-67-premium/  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://dealbook.nytimes.com/2010/03/09/abbott-to-buy-facet-biotech-for-67-premium/'" tppabs="https://dealbook.nytimes.com/2010/03/09/abbott-to-buy-facet-biotech-for-67-premium/" class="external text external">Abbott to Buy Facet Biotech for 67% Premium</a></span></li><li id="cite_note-29"> <span id="mw-reference-text-cite_note-29" class="mw-reference-text"><a href="javascript:if(confirm('https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm504000.htm  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm504000.htm'" tppabs="https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm504000.htm" class="external text external">FDA News Release: FDA approves Zinbryta to treat multiple sclerosis</a> May 27, 2016</span></li><li id="cite_note-pmid18268208-30"> <span id="mw-reference-text-cite_note-pmid18268208-30" class="mw-reference-text"><cite id="CITEREFSobrinHuangChristenKafkala2008" class="citation journal cs1">Sobrin L, Huang JJ, Christen W, Kafkala C, Choopong P, Foster CS (February 2008). "Daclizumab for treatment of birdshot chorioretinopathy". <i>Archives of Ophthalmology</i>. <b>126</b> (2): 186–91. doi:<a href="javascript:if(confirm('https://doi.org/10.1001%2Farchophthalmol.2007.49  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1001%2Farchophthalmol.2007.49'" tppabs="https://doi.org/10.1001%2Farchophthalmol.2007.49" class="external text external">10.1001/archophthalmol.2007.49</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/18268208  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/18268208'" tppabs="https://pubmed.ncbi.nlm.nih.gov/18268208" class="external text external">18268208</a>.</cite></span></li></ol></div>

<div role="navigation" class="navbox" aria-labelledby="Immunosuppressive_drugs_/_Immunosuppressants_(L04)" style="padding:3px"><table class="nowraplinks mw-collapsible autocollapse navbox-inner" style="border-spacing:0;background:transparent;color:inherit"><tbody><tr><th scope="col" class="navbox-title" colspan="2"><div id="Immunosuppressive_drugs_/_Immunosuppressants_(L04)" style="font-size:114%;margin:0 4em">Immunosuppressive drugs<span>&nbsp;</span>/ Immunosuppressants (L04)</div></th></tr><tr><th scope="row" class="navbox-group" style="width:1%">Intracellular<br>(initiation)</th><td class="navbox-list navbox-odd hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em"></div><table class="nowraplinks navbox-subgroup" style="border-spacing:0"><tbody><tr><th scope="row" class="navbox-group" style="width:1%">Antimetabolites</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>purine synthesis inhibitors</i>
<ul><li><a href="Azathioprine.htm" tppabs="https://ptable.com/wiki/compounds/A/Azathioprine" title="Azathioprine">Azathioprine</a></li>
<li><a href="Mycophenolic_acid.htm" tppabs="https://ptable.com/wiki/compounds/A/Mycophenolic_acid" title="Mycophenolic acid">Mycophenolic acid</a></li></ul></li></ul>

<ul><li><i>pyrimidine synthesis inhibitors</i>
<ul><li><a href="Leflunomide.htm" tppabs="https://ptable.com/wiki/compounds/A/Leflunomide" title="Leflunomide">Leflunomide</a></li>
<li>Teriflunomide</li></ul></li></ul>

<ul><li><i>antifolate</i>
<ul><li><a href="Methotrexate.htm" tppabs="https://ptable.com/wiki/compounds/A/Methotrexate" title="Methotrexate">Methotrexate</a></li></ul></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Macrolides/<br>other <a href="Interleukin_2.htm" tppabs="https://ptable.com/wiki/compounds/A/Interleukin_2" title="Interleukin 2">IL-2</a> inhibitors</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>FKBP/Cyclophilin/Calcineurin</i>
<ul><li><a href="Tacrolimus.htm" tppabs="https://ptable.com/wiki/compounds/A/Tacrolimus" title="Tacrolimus">Tacrolimus</a></li>
<li><a href="Ciclosporin.htm" tppabs="https://ptable.com/wiki/compounds/A/Ciclosporin" title="Ciclosporin">Ciclosporin</a></li>
<li><a href="Pimecrolimus.htm" tppabs="https://ptable.com/wiki/compounds/A/Pimecrolimus" title="Pimecrolimus">Pimecrolimus</a></li></ul></li></ul>

<ul><li>Abetimus</li>
<li>Gusperimus</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">IMiDs</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><a href="Lenalidomide.htm" tppabs="https://ptable.com/wiki/compounds/A/Lenalidomide" title="Lenalidomide">Lenalidomide</a></li>
<li>Pomalidomide</li>
<li><a href="Thalidomide.htm" tppabs="https://ptable.com/wiki/compounds/A/Thalidomide" title="Thalidomide">Thalidomide</a></li>
<li><i>PDE4 inhibitor</i>
<ul><li>Apremilast</li></ul></li></ul>
</div></td></tr></tbody></table><div></div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Intracellular<br>(reception)</th><td class="navbox-list navbox-odd hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em"></div><table class="nowraplinks navbox-subgroup" style="border-spacing:0"><tbody><tr><th scope="row" class="navbox-group" style="width:1%">IL-1 receptor antagonists</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><a href="Anakinra.htm" tppabs="https://ptable.com/wiki/compounds/A/Anakinra" title="Anakinra">Anakinra</a></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">mTOR</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><a href="Sirolimus.htm" tppabs="https://ptable.com/wiki/compounds/A/Sirolimus" title="Sirolimus">Sirolimus</a></li>
<li><a href="Everolimus.htm" tppabs="https://ptable.com/wiki/compounds/A/Everolimus" title="Everolimus">Everolimus</a></li>
<li>Ridaforolimus</li>
<li><a href="Temsirolimus.htm" tppabs="https://ptable.com/wiki/compounds/A/Temsirolimus" title="Temsirolimus">Temsirolimus</a></li>
<li>Umirolimus</li>
<li>Zotarolimus</li></ul>
</div></td></tr></tbody></table><div></div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Extracellular</th><td class="navbox-list navbox-odd hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em"></div><table class="nowraplinks navbox-subgroup" style="border-spacing:0"><tbody><tr><th scope="row" class="navbox-group" style="width:1%"><a href="Antibody.htm" tppabs="https://ptable.com/wiki/compounds/A/Antibody" title="Antibody">Antibodies</a></th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em"></div><table class="nowraplinks navbox-subgroup" style="border-spacing:0"><tbody><tr><th scope="row" class="navbox-group" style="width:1%">Monoclonal</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em"></div><table class="nowraplinks navbox-subgroup" style="border-spacing:0"><tbody><tr><th scope="row" class="navbox-group" style="width:1%">Serum target<br>(noncellular)</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Complement component 5</i>
<ul><li>Eculizumab</li></ul></li>
<li><i>TNF</i>
<ul><li><a href="Adalimumab.htm" tppabs="https://ptable.com/wiki/compounds/A/Adalimumab" title="Adalimumab">Adalimumab</a></li>
<li>Afelimomab</li>
<li>Certolizumab pegol</li>
<li>Golimumab</li>
<li><a href="Infliximab.htm" tppabs="https://ptable.com/wiki/compounds/A/Infliximab" title="Infliximab">Infliximab</a></li>
<li>Nerelimomab</li></ul></li>
<li><i>Interleukin 5</i>
<ul><li>Mepolizumab</li></ul></li>
<li><i>Immunoglobulin E</i>
<ul><li><a href="Omalizumab.htm" tppabs="https://ptable.com/wiki/compounds/A/Omalizumab" title="Omalizumab">Omalizumab</a></li></ul></li></ul>

<ul><li><i>Interferon</i>
<ul><li>Faralimomab</li></ul></li></ul>

<ul><li><i>IL-6</i>
<ul><li>Elsilimomab</li></ul></li></ul>

<ul><li><i>IL-12 and IL-23</i>
<ul><li>Lebrikizumab</li>
<li>Ustekinumab</li></ul></li></ul>

<ul><li><i>IL-17A</i>
<ul><li>Secukinumab</li></ul></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Cellular<br>target</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>CD3</i>
<ul><li><a href="Muromonab-CD3.htm" tppabs="https://ptable.com/wiki/compounds/A/Muromonab-CD3" title="Muromonab-CD3">Muromonab-CD3</a></li>
<li>Otelixizumab</li>
<li>Teplizumab</li>
<li>Visilizumab</li></ul></li>
<li><i>CD4</i>
<ul><li>Clenoliximab</li>
<li>Keliximab</li>
<li>Zanolimumab</li></ul></li>
<li><i>CD11a</i>
<ul><li>Efalizumab</li></ul></li>
<li><i>CD18</i>
<ul><li>Erlizumab</li></ul></li>
<li><i>CD20</i>
<ul><li>Obinutuzumab</li>
<li><a href="Rituximab.htm" tppabs="https://ptable.com/wiki/compounds/A/Rituximab" title="Rituximab">Rituximab</a></li>
<li>Ocrelizumab</li>
<li>Pascolizumab</li></ul></li>
<li><i>CD23</i>
<ul><li>Gomiliximab</li>
<li>Lumiliximab</li></ul></li>
<li><i>CD40</i>
<ul><li>Teneliximab</li>
<li>Toralizumab</li></ul></li>
<li><i>CD62L/L-selectin</i>
<ul><li>Aselizumab</li></ul></li>
<li><i>CD80</i>
<ul><li>Galiximab</li></ul></li>
<li><i>CD147/Basigin</i>
<ul><li>Gavilimomab</li></ul></li>
<li><i>CD154</i>
<ul><li>Ruplizumab</li></ul></li></ul>

<ul><li><i>BLyS</i>
<ul><li>Belimumab</li>
<li>Blisibimod</li></ul></li>
<li><i>CTLA-4</i>
<ul><li>Ipilimumab</li>
<li>Tremelimumab</li></ul></li>
<li><i>CAT</i>
<ul><li>Bertilimumab</li>
<li>Lerdelimumab</li>
<li>Metelimumab</li></ul></li>
<li><i>Integrin</i>
<ul><li>Natalizumab</li>
<li>Vedolizumab</li></ul></li>
<li><i>Interleukin-6 receptor</i>
<ul><li>Tocilizumab</li></ul></li>
<li><i>LFA-1</i>
<ul><li>Odulimomab</li></ul></li></ul>

<ul><li><i>IL-2 receptor/CD25</i>
<ul><li><a href="Basiliximab.htm" tppabs="https://ptable.com/wiki/compounds/A/Basiliximab" title="Basiliximab">Basiliximab</a></li>
<li><a href="Daclizumab.htm" tppabs="https://ptable.com/wiki/compounds/A/Daclizumab" title="Daclizumab">Daclizumab</a></li>
<li>Inolimomab</li></ul></li></ul>

<ul><li><i>T-lymphocyte</i> (Zolimomab aritox)</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Unsorted</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>Atorolimumab</li>
<li>Cedelizumab</li>
<li>Fontolizumab</li>
<li>Maslimomab</li>
<li>Morolimumab</li>
<li>Pexelizumab</li>
<li>Reslizumab</li>
<li>Rovelizumab</li>
<li>Siplizumab</li>
<li>Talizumab</li>
<li>Telimomab aritox</li>
<li>Vapaliximab</li>
<li>Vepalimomab</li></ul>
</div></td></tr></tbody></table><div></div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Polyclonal</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>Anti-thymocyte globulin</li>
<li>Anti-lymphocyte globulin</li></ul>
</div></td></tr></tbody></table><div></div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">-cept (Fusion)</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>CTLA-4</i>
<ul><li>Abatacept</li>
<li>Belatacept</li></ul></li>
<li><i>TNF inhibitor</i>
<ul><li><a href="Etanercept.htm" tppabs="https://ptable.com/wiki/compounds/A/Etanercept" title="Etanercept">Etanercept</a></li>
<li>Pegsunercept</li></ul></li>
<li>Aflibercept</li>
<li><a href="Alefacept.htm" tppabs="https://ptable.com/wiki/compounds/A/Alefacept" title="Alefacept">Alefacept</a></li>
<li>Rilonacept</li></ul>
</div></td></tr></tbody></table><div></div></td></tr></tbody></table></div>
<div role="navigation" class="navbox" aria-labelledby="Monoclonal_antibodies_for_the_immune_system" style="padding:3px"><table class="nowraplinks mw-collapsible autocollapse navbox-inner" style="border-spacing:0;background:transparent;color:inherit"><tbody><tr><th scope="col" class="navbox-title" colspan="2" style="text-align:center;"><div id="Monoclonal_antibodies_for_the_immune_system" style="font-size:114%;margin:0 4em">Monoclonal antibodies for the immune system</div></th></tr><tr><th scope="row" class="navbox-group" style="text-align:center;;width:1%">Immune system</th><td class="navbox-list navbox-odd hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em"></div><table class="nowraplinks navbox-subgroup" style="border-spacing:0"><tbody><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">Human</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Immunosuppression</i>: Abrilumab</li>
<li><a href="Adalimumab.htm" tppabs="https://ptable.com/wiki/compounds/A/Adalimumab" title="Adalimumab">Adalimumab</a></li>
<li>Anifrolumab<sup>†</sup></li>
<li>Atorolimumab</li>
<li>Avelumab</li>
<li>Belimumab</li>
<li>Bleselumab</li>
<li>Brodalumab</li>
<li>Camidanlumab tesirine</li>
<li>Carlumab</li>
<li>Cemiplimab</li>
<li>Dupilumab</li>
<li>Eldelumab</li>
<li>Emapalumab<sup>†</sup></li>
<li>Fresolimumab</li>
<li>Golimumab</li>
<li>Ianalumab<sup>†</sup></li>
<li>Lanadelumab</li>
<li>Lenzilumab</li>
<li>Lerdelimumab</li>
<li>Lirilumab</li>
<li>Mavrilimumab</li>
<li>Metelimumab</li>
<li>Morolimumab</li>
<li>Namilumab</li>
<li>Oleclumab</li>
<li>Oxelumab§</li>
<li>Pamrevlumab</li>
<li>Placulumab</li>
<li>Relatlimab<sup>†</sup></li>
<li>Sarilumab</li>
<li>Sifalimumab</li>
<li>Tabalumab</li>
<li>Tezepelumab<sup>†</sup></li>
<li>Ulocuplumab</li>
<li>Varlilumab</li></ul>

<ul><li><i>Immune activation</i>: Ipilimumab</li>
<li>Atezolizumab</li>
<li>Durvalumab</li>
<li>Nivolumab</li>
<li>Pembrolizumab</li>
<li>Tremelimumab<sup>†</sup></li>
<li>Urelumab</li></ul>

<ul><li><i>Other</i>: Bertilimumab</li>
<li>Zanolimumab</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">Mouse</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>Afelimomab</li>
<li>Elsilimomab</li>
<li>Faralimomab</li>
<li>Gavilimomab</li>
<li>Inolimomab</li>
<li>Maslimomab</li>
<li>Nerelimomab</li>
<li>Odulimomab</li>
<li>Telimomab aritox</li>
<li>Vepalimomab</li>
<li>Zolimomab aritox</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">Chimeric</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>Andecaliximab<sup>†</sup></li>
<li><a href="Basiliximab.htm" tppabs="https://ptable.com/wiki/compounds/A/Basiliximab" title="Basiliximab">Basiliximab</a></li>
<li>Clenoliximab</li>
<li>Galiximab</li>
<li>Gomiliximab</li>
<li><a href="Infliximab.htm" tppabs="https://ptable.com/wiki/compounds/A/Infliximab" title="Infliximab">Infliximab</a></li>
<li>Keliximab</li>
<li>Lumiliximab</li>
<li>Priliximab</li>
<li>Teneliximab</li>
<li>Vapaliximab</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">Humanized</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Immunosuppressive:</i> Aselizumab</li>
<li>Apolizumab<sup>§</sup></li>
<li>Benralizumab</li>
<li>Camrelizumab<sup>†</sup></li>
<li>Cedelizumab</li>
<li>Certolizumab pegol</li>
<li>Crizanlizumab<sup>†</sup></li>
<li><a href="Daclizumab.htm" tppabs="https://ptable.com/wiki/compounds/A/Daclizumab" title="Daclizumab">Daclizumab</a></li>
<li>Dostarlimab<sup>†</sup></li>
<li>Eculizumab</li>
<li>Efalizumab<sup>‡</sup></li>
<li>Epratuzumab</li>
<li>Erlizumab</li>
<li>Etrolizumab<sup>†</sup></li>
<li>Fontolizumab</li>
<li>Inebilizumab</li>
<li>Itolizumab</li>
<li>Lampalizumab<sup>†</sup></li>
<li>Letolizumab</li>
<li>Ligelizumab<sup>†</sup></li>
<li>Lulizumab pegol</li>
<li>Mepolizumab</li>
<li>Mogamulizumab</li>
<li>Natalizumab</li>
<li>Ocrelizumab</li>
<li><a href="Omalizumab.htm" tppabs="https://ptable.com/wiki/compounds/A/Omalizumab" title="Omalizumab">Omalizumab</a></li>
<li>Ozoralizumab</li>
<li>Pascolizumab</li>
<li>Pateclizumab</li>
<li>Pembrolizumab</li>
<li>Pexelizumab</li>
<li>Pidilizumab</li>
<li>Plozalizumab</li>
<li>PRO 140<sup>†</sup></li>
<li>Quilizumab</li>
<li>Ravulizumab</li>
<li>Reslizumab</li>
<li>Rontalizumab</li>
<li>Rovelizumab</li>
<li>Ruplizumab</li>
<li>Samalizumab</li>
<li>Satralizumab</li>
<li>Siplizumab</li>
<li>Spartalizumab<sup>†</sup></li>
<li>Talizumab</li>
<li>Teplizumab</li>
<li>Tislelizumab</li>
<li>Tocilizumab</li>
<li>Toralizumab</li>
<li>Tregalizumab</li>
<li>Vatelizumab</li>
<li>Vedolizumab</li>
<li>Visilizumab</li>
<li>Vobarilizumab</li>
<li>TGN1412<sup>§</sup><br><i>Non-immunosuppressive:</i> Ibalizumab</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">Chimeric + humanized<br></th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>Otelixizumab</li>
<li>Sutimlimab<sup>†</sup></li></ul>
</div></td></tr></tbody></table><div></div></td></tr><tr><th scope="row" class="navbox-group" style="text-align:center;;width:1%">Interleukin</th><td class="navbox-list navbox-odd hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em"></div><table class="nowraplinks navbox-subgroup" style="border-spacing:0"><tbody><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">Human</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>Bermekimab</li>
<li>Brazikumab</li>
<li>Briakinumab</li>
<li>Canakinumab</li>
<li>Fezakinumab</li>
<li>Fletikumab</li>
<li>Guselkumab</li>
<li>Secukinumab</li>
<li>Sirukumab</li>
<li>Tralokinumab<sup>†</sup></li>
<li>Ustekinumab</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">Humanized</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>Anrukinzumab</li>
<li>Bimekizumab<sup>†</sup></li>
<li>Clazakizumab</li>
<li>Gevokizumab</li>
<li>Ixekizumab</li>
<li>Mirikizumab<sup>†</sup></li>
<li>Lebrikizumab</li>
<li>Olokizumab<sup>†</sup></li>
<li>Perakizumab</li>
<li>Risankizumab</li>
<li>Tildrakizumab</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">Veterinary</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>Lokivetmab</li></ul>
</div></td></tr></tbody></table><div></div></td></tr><tr><th scope="row" class="navbox-group" style="text-align:center;;width:1%">Inflammatory lesions</th><td class="navbox-list navbox-odd hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em"></div><table class="nowraplinks navbox-subgroup" style="border-spacing:0"><tbody><tr><th id="Mouse" scope="row" class="navbox-group" style="width:1%;text-align:center;">Mouse</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>Besilesomab</li>
<li>Fanolesomab<sup>‡</sup></li>
<li>Lemalesomab</li>
<li>Sulesomab</li></ul>
</div></td></tr></tbody></table><div></div></td></tr><tr><td class="navbox-abovebelow" colspan="2" style="text-align:center;;background: transparent; padding: 0px;"><div><div class="hlist">
<ul><li><sup>#</sup>WHO-EM</li>
<li><sup>‡</sup>Withdrawn from market</li>
<li>Clinical trials:
<ul><li><sup>†</sup>Phase III</li>
<li><sup>§</sup>Never to phase III</li></ul></li></ul>
</div></div></td></tr></tbody></table></div>
<div role="navigation" class="navbox" aria-labelledby="Interleukin_receptor_modulators" style="padding:3px"><table class="nowraplinks hlist mw-collapsible mw-collapsed navbox-inner" style="border-spacing:0;background:transparent;color:inherit"><tbody><tr><th scope="col" class="navbox-title" colspan="2"><div id="Interleukin_receptor_modulators" style="font-size:114%;margin:0 4em">Interleukin receptor modulators</div></th></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">IL-1</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Agonists:</i> Interleukin 1 (α, β)</li>
<li><span class="new">Mobenakin</span></li>
<li><span class="new">Pifonakin</span></li></ul>

<ul><li><i>Antagonists:</i> <span class="new">AF-12198</span></li>
<li><a href="Anakinra.htm" tppabs="https://ptable.com/wiki/compounds/A/Anakinra" title="Anakinra">Anakinra</a></li>
<li>IL-1RA</li>
<li><span class="new">Isunakinra</span></li></ul>

<ul><li><i>Antibodies:</i> Canakinumab</li>
<li>Gevokizumab</li>
<li><span class="new">Lutikizumab</span></li></ul>

<ul><li><i>Decoy receptors:</i> Rilonacept (IL-1 Trap)</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">IL-2</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Agonists:</i> <span class="new">Adargileukin alfa</span></li>
<li><a href="Interleukin_2.htm" tppabs="https://ptable.com/wiki/compounds/A/Aldesleukin" title="Aldesleukin" class="mw-redirect">Aldesleukin</a></li>
<li><span class="new">Celmoleukin</span></li>
<li><a href="Denileukin_diftitox.htm" tppabs="https://ptable.com/wiki/compounds/A/Denileukin_diftitox" title="Denileukin diftitox">Denileukin diftitox</a></li>
<li><a href="Interleukin_2.htm" tppabs="https://ptable.com/wiki/compounds/A/Interleukin_2" title="Interleukin 2">Interleukin 2</a></li>
<li><span class="new">Pegaldesleukin</span></li>
<li><span class="new">Teceleukin</span></li>
<li>Tucotuzumab celmoleukin</li></ul>

<ul><li><i>Antibodies:</i> <a href="Basiliximab.htm" tppabs="https://ptable.com/wiki/compounds/A/Basiliximab" title="Basiliximab">Basiliximab</a></li>
<li><a href="Daclizumab.htm" tppabs="https://ptable.com/wiki/compounds/A/Daclizumab" title="Daclizumab">Daclizumab (dacliximab)</a></li>
<li>Inolimomab</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">IL-3</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Agonists:</i> <span class="new">Daniplestim</span></li>
<li>Interleukin 3</li>
<li><span class="new">Leridistim</span></li>
<li><span class="new">Milodistim</span></li>
<li><span class="new">Muplestim</span></li>
<li>Promegapoietin</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">IL-4</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Agonists:</i> <span class="new">Binetrakin</span></li>
<li>Interleukin 4</li>
<li>Interleukin 13</li></ul>

<ul><li><i>Antagonists:</i> Pitrakinra</li></ul>

<ul><li><i>Antibodies:</i> Dupilumab</li>
<li>Pascolizumab</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">IL-5</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Agonists:</i> Interleukin 5</li></ul>

<ul><li><i>Antagonists:</i> <span class="new">YM-90709</span></li></ul>

<ul><li><i>Antibodies:</i> Benralizumab</li>
<li>Mepolizumab</li>
<li>Reslizumab</li></ul>

<ul><li><i>Antisense oligonucleotides:</i> <span class="new">TPI ASM8</span></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">IL-6</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Agonists:</i> <span class="new">Atexakin alfa</span></li>
<li>Interleukin 6</li></ul>

<ul><li><i>Antibodies:</i> <span class="new">ARGX-109</span></li>
<li>Clazakizumab</li>
<li>Elsilimomab</li>
<li><span class="new">mAb 1339</span></li>
<li>Olokizumab</li>
<li>Sarilumab</li>
<li>Siltuximab</li>
<li>Sirukumab</li>
<li>Tocilizumab</li>
<li><span class="new">Levilimab</span></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">IL-7</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Agonists:</i> Interleukin 7</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">IL-8</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>See CXCR1 (IL-8Rα) and CXCR2 (IL-8Rβ) here instead.</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">IL-9</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Agonists:</i> Interleukin 9</li></ul>

<ul><li><i>Antibodies:</i> <span class="new">Enokizumab</span></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">IL-10</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Agonists:</i> <span class="new">Ilodecakin</span></li>
<li>Interleukin 10 (CSIF)</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">IL-11</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Agonists:</i> Interleukin 11 (AGIF)</li>
<li><a href="Oprelvekin.htm" tppabs="https://ptable.com/wiki/compounds/A/Oprelvekin" title="Oprelvekin">Oprelvekin</a></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">IL-12</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Agonists:</i> <span class="new">Edodekin alfa</span></li>
<li>Interleukin 12</li></ul>

<ul><li><i>Antibodies:</i> Briakinumab</li>
<li>Ustekinumab</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">IL-13</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Agonists:</i> <span class="new">Binetrakin</span></li>
<li><span class="new">Cintredekin besudotox</span></li>
<li>Interleukin 4</li>
<li>Interleukin 13</li></ul>

<ul><li><i>Antibodies:</i> Anrukinzumab</li>
<li>Lebrikizumab</li>
<li>Tralokinumab</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">IL-15</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Agonists:</i> ALT-803</li>
<li>Interleukin 15</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">IL-17</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Agonists:</i> Interleukin 17 (A, <span class="new">B</span>, <span class="new">C</span>, <span class="new">D</span>, E (interleukin 25), <span class="new">F</span>)</li></ul>

<ul><li><i>Antibodies:</i> Brodalumab</li>
<li>Ixekizumab</li>
<li>Perakizumab</li>
<li><span class="new">Remtolumab</span></li>
<li>Secukinumab</li>
<li><span class="new">Vunakizumab</span></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">IL-18</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Agonists:</i> <span class="new">Iboctadekin</span></li>
<li>Interleukin 18</li>
<li>Interleukin 37</li>
<li><span class="new">Tadekinig</span></li></ul>

<ul><li><i>Binding proteins:</i> IL18BP</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">IL-20</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Agonists:</i> Interleukin 19</li>
<li>Interleukin 20</li>
<li>Interleukin 24</li></ul>

<ul><li><i>Antibodies:</i> Fletikumab (against IL-20)</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">IL-21</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Agonists:</i> <span class="new">Denenicokin</span></li>
<li>Interleukin 21</li></ul>

<ul><li><i>Antibodies:</i> <span class="new">NNC0114-0005</span></li>
<li><span class="new">NNC0114-0006</span></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">IL-22</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Agonists:</i> Interleukin 22</li></ul>

<ul><li><i>Antibodies:</i> Fezakinumab (against IL-22)</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">IL-23</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Agonists:</i> Interleukin 23 (SGRF)</li></ul>

<ul><li><i>Antibodies:</i> Brazikumab</li>
<li>Briakinumab</li>
<li>Guselkumab</li>
<li>Risankizumab</li>
<li>Tildrakizumab</li>
<li>Ustekinumab</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">IL-27</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Agonists:</i> Interleukin 27 (interleukin 30)</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">IL-28</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Agonists:</i> <span class="new">Interferon λ4 (IFN-λ4)</span></li>
<li>Interleukin 28 (<span class="new">A (IFN-λ2)</span>, B (IFN-λ3))</li>
<li>Interleukin-29 (IFN-λ1)</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">IL-31</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Agonists:</i> Interleukin 31</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">IL1RL1</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Agonists:</i> Interleukin 33</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">IL1RL2</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Agonists:</i> Interleukin 36 (α, β, γ)</li>
<li>Interleukin 38</li></ul>

<ul><li><i>Antagonists:</i> IL-36RA</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">Others</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em"></div><table class="nowraplinks navbox-subgroup" style="border-spacing:0"><tbody><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">JAK</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>See here instead.</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">Others</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>Interleukin 14 (taxilin alpha, HMW-BCGF)</li>
<li>Interleukin 16 (signals through CD4)</li>
<li>Interleukin 24 (signals through IL-22Rα1/IL-20Rβ heterodimer)</li>
<li>Interleukin 26 (signals through IL-20Rα/IL-10Rβ heterodimer)</li>
<li>Interleukin 32</li>
<li>Interleukin 34 (signals through M-CSFR/CSF1R)</li>
<li>Interleukin 35</li></ul>

<ul><li><i>Unsorted:</i> <span class="new">Efavaleukin alfa</span></li>
<li><span class="new">Efineptakin alfa</span></li></ul>
</div></td></tr></tbody></table><div></div></td></tr><tr><td class="navbox-abovebelow" colspan="2"><div>
<dl><dt>See also</dt>
<dd><i>Receptor/signaling modulators</i></dd>
<dd><i>Signaling peptide/protein receptor modulators</i></dd>
<dd><i>Cytokine receptor modulators</i></dd></dl>
</div></td></tr></tbody></table></div>




<style data-mw-deduplicate="TemplateStyles:r951705291">.mw-parser-output cite.citation{font-style:inherit}.mw-parser-output .citation q{quotes:"\"""\"""'""'"}.mw-parser-output .id-lock-free a,.mw-parser-output .citation .cs1-lock-free a{background-image:url("../../../../upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/9px-Lock-green.svg.png"/*tpa=https://upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/9px-Lock-green.svg.png*/);background-image:linear-gradient(transparent,transparent),url("../../../../upload.wikimedia.org/wikipedia/commons/6/65/Lock-green.svg"/*tpa=https://upload.wikimedia.org/wikipedia/commons/6/65/Lock-green.svg*/);background-repeat:no-repeat;background-size:9px;background-position:right .1em center}.mw-parser-output .id-lock-limited a,.mw-parser-output .id-lock-registration a,.mw-parser-output .citation .cs1-lock-limited a,.mw-parser-output .citation .cs1-lock-registration a{background-image:url("../../../../upload.wikimedia.org/wikipedia/commons/thumb/d/d6/Lock-gray-alt-2.svg/9px-Lock-gray-alt-2.svg.png"/*tpa=https://upload.wikimedia.org/wikipedia/commons/thumb/d/d6/Lock-gray-alt-2.svg/9px-Lock-gray-alt-2.svg.png*/);background-image:linear-gradient(transparent,transparent),url("../../../../upload.wikimedia.org/wikipedia/commons/d/d6/Lock-gray-alt-2.svg"/*tpa=https://upload.wikimedia.org/wikipedia/commons/d/d6/Lock-gray-alt-2.svg*/);background-repeat:no-repeat;background-size:9px;background-position:right .1em center}.mw-parser-output .id-lock-subscription a,.mw-parser-output .citation .cs1-lock-subscription a{background-image:url("../../../../upload.wikimedia.org/wikipedia/commons/thumb/a/aa/Lock-red-alt-2.svg/9px-Lock-red-alt-2.svg.png"/*tpa=https://upload.wikimedia.org/wikipedia/commons/thumb/a/aa/Lock-red-alt-2.svg/9px-Lock-red-alt-2.svg.png*/);background-image:linear-gradient(transparent,transparent),url("../../../../upload.wikimedia.org/wikipedia/commons/a/aa/Lock-red-alt-2.svg"/*tpa=https://upload.wikimedia.org/wikipedia/commons/a/aa/Lock-red-alt-2.svg*/);background-repeat:no-repeat;background-size:9px;background-position:right .1em center}.mw-parser-output .cs1-subscription,.mw-parser-output .cs1-registration{color:#555}.mw-parser-output .cs1-subscription span,.mw-parser-output .cs1-registration span{border-bottom:1px dotted;cursor:help}.mw-parser-output .cs1-ws-icon a{background-image:url("../../../../upload.wikimedia.org/wikipedia/commons/thumb/4/4c/Wikisource-logo.svg/12px-Wikisource-logo.svg.png"/*tpa=https://upload.wikimedia.org/wikipedia/commons/thumb/4/4c/Wikisource-logo.svg/12px-Wikisource-logo.svg.png*/);background-image:linear-gradient(transparent,transparent),url("../../../../upload.wikimedia.org/wikipedia/commons/4/4c/Wikisource-logo.svg"/*tpa=https://upload.wikimedia.org/wikipedia/commons/4/4c/Wikisource-logo.svg*/);background-repeat:no-repeat;background-size:12px;background-position:right .1em center}.mw-parser-output code.cs1-code{color:inherit;background:inherit;border:inherit;padding:inherit}.mw-parser-output .cs1-hidden-error{display:none;font-size:100%}.mw-parser-output .cs1-visible-error{font-size:100%}.mw-parser-output .cs1-maint{display:none;color:#33aa33;margin-left:0.3em}.mw-parser-output .cs1-subscription,.mw-parser-output .cs1-registration,.mw-parser-output .cs1-format{font-size:95%}.mw-parser-output .cs1-kern-left,.mw-parser-output .cs1-kern-wl-left{padding-left:0.2em}.mw-parser-output .cs1-kern-right,.mw-parser-output .cs1-kern-wl-right{padding-right:0.2em}.mw-parser-output .citation .mw-selflink{font-weight:inherit}</style>
    
</details><!--htdig_noindex--><div><div style="clear:both; background-image:linear-gradient(180deg, #E8E8E8, white); border-top: dashed 2px #AAAAAA; padding: 0.5em 0.5em 0.5em 0.5em; margin-top: 1em; direction: ltr;">
    This article is issued from <a class="external text" title="Last edited on 2020-08-09" href="javascript:if(confirm('https://en.wikipedia.org/wiki/?title=Daclizumab&oldid=972042502  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://en.wikipedia.org/wiki/?title=Daclizumab&oldid=972042502'" tppabs="https://en.wikipedia.org/wiki/?title=Daclizumab&oldid=972042502">Wikipedia</a>. The text is licensed under <a class="external text" href="javascript:if(confirm('https://creativecommons.org/licenses/by-sa/4.0/  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://creativecommons.org/licenses/by-sa/4.0/'" tppabs="https://creativecommons.org/licenses/by-sa/4.0/">Creative Commons - Attribution - Sharealike</a>. Additional terms may apply for the media files.
</div>
</div><!--/htdig_noindex--></div>
        </div>
      </div>
    </div>
  </div>
  <script src="../-/j/js_modules/jsConfigVars.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/jsConfigVars.js" class=""></script>
  <script src="../-/j/js_modules/startup.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/startup.js" class=""></script>
<script src="../-/j/js_modules/jquery.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/jquery.js" class=""></script>
<script src="../-/j/js_modules/mediawiki.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/mediawiki.js" class=""></script>
<script src="../-/j/js_modules/site.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/site.js" class=""></script>
<script src="../-/j/js_modules/ext.cite.ux-enhancements.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/ext.cite.ux-enhancements.js" class=""></script>



</body></html>